Juno Therapeutics

Biotechnology

Juno Therapeutics (acquired by Celgene/Bristol-Myers Squibb) was an early leader in CAR-T cell therapy development before acquisition. The company's trials helped define safety protocols for cellular immunotherapies. Juno's acquisition reflected the strategic importance of cell therapy capabilities for large pharmaceutical companies.

The Biology of Business

Sign up to be notified when the book is available to order.

Notify Me